| Joel Robert Saul, DO | |
|
1885 Ne Purcell Blvd, Bend, OR 97701-6022 | |
| (541) 706-2715 | |
| Not Available |
| Full Name | Joel Robert Saul |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 1885 Ne Purcell Blvd, Bend, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609280387 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | LL36694 (South Carolina) | Primary |
| Entity Name | Ubh Of Oregon Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528231826 PECOS PAC ID: 4981772639 Enrollment ID: O20091007000334 |
News Archive
Researchers of Ghent University - department of Food Safety and food Quality developped a technique to to reduce acrylamide in French fries on an industrial scale. Acrylamide is a product that may cause cancer and was discovered in various foods.
Following the commercial launch of Seralite - FLC Abingdon Health is looking to appoint distributors in order to enable as many people as possible affected by multiple myeloma (a cancer arising from plasma cells) to have access to, and benefit from its rapid diagnostic capabilities.
Scientists have discovered that measuring brainwaves produced during REM sleep can predict whether a patient will respond to treatment from depression.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today announced that the first patients have been enrolled in its COSIRA trial designed to assess the clinical efficacy of the Neovasc Reducer(TM) product for the treatment of refractory angina. The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial is a multicenter, sham-controlled, randomized, double-blinded study of the Reducer that is expected to enroll up to 124 patients.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joel Robert Saul, DO 1 Independence Pt, Suite 212, Greenville, SC 29615-4545 Ph: (864) 797-6306 | Joel Robert Saul, DO 1885 Ne Purcell Blvd, Bend, OR 97701-6022 Ph: (541) 706-2715 |
News Archive
Researchers of Ghent University - department of Food Safety and food Quality developped a technique to to reduce acrylamide in French fries on an industrial scale. Acrylamide is a product that may cause cancer and was discovered in various foods.
Following the commercial launch of Seralite - FLC Abingdon Health is looking to appoint distributors in order to enable as many people as possible affected by multiple myeloma (a cancer arising from plasma cells) to have access to, and benefit from its rapid diagnostic capabilities.
Scientists have discovered that measuring brainwaves produced during REM sleep can predict whether a patient will respond to treatment from depression.
Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today announced that the first patients have been enrolled in its COSIRA trial designed to assess the clinical efficacy of the Neovasc Reducer(TM) product for the treatment of refractory angina. The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial is a multicenter, sham-controlled, randomized, double-blinded study of the Reducer that is expected to enroll up to 124 patients.
› Verified 5 days ago
Dr. Anne Elizabeth Linton, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 62635 Nw Mt Thielsen Dr Unit 1, Bend, OR 97703 Phone: 503-928-0226 | |
Dr. Elliot Morrison, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 22025 Ne Butler Market Rd, Bend, OR 97701 Phone: 541-383-0764 | |
Jeremiah W Lanford, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2450 Ne Mary Rose Pl Ste 210, Bend, OR 97701 Phone: 541-706-5770 Fax: 541-429-6669 | |
Laura Joelle Schaben, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2349 Ne Conners Ave, Bend, OR 97701 Phone: 541-317-0044 Fax: 541-728-0707 | |
Terry D Rolan, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1501 Ne Medical Center Dr, Bend, OR 97701 Phone: 541-382-4900 | |
Michelle Cohen, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2500 Ne Neff Rd, Bend, OR 97701 Phone: 541-706-6892 | |
Shane M Coleman, M.D., MPH Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2600 Ne Neff Rd, Bend, OR 97701 Phone: 541-706-4800 Fax: 541-706-4806 |